Holen Sie sich die Stockscreener-App
1.02
1.92%
-0.02
Schlusskurs vom Vortag:
$1.04
Offen:
$1.06
24-Stunden-Volumen:
65,035
Relative Volume:
0.41
Marktkapitalisierung:
$11.85M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-10.93M
KGV:
-0.7094
EPS:
-1.4378
Netto-Cashflow:
$-10.72M
1W Leistung:
+2.00%
1M Leistung:
-3.77%
6M Leistung:
-12.07%
1J Leistung:
-58.28%
1-Tages-Spanne:
$1.015
$1.06
1-Wochen-Bereich:
$0.9774
$1.1001
52-Wochen-Spanne:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Firmenname
Phio Pharmaceuticals Corp
Sektor
Branche
Telefon
(508) 767-3861
Adresse
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.02 | 11.85M | 0 | -10.93M | -10.72M | -1.4378 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-05 | Eingeleitet | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
PHIO Q1 2026 Earnings: EPS Misses Estimates as Biotech Continues Clinical DevelopmentAnalyst Earnings Estimate - dars.gov.et
PHIO PE Ratio & Valuation, Is PHIO Overvalued - Intellectia AI
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock - Investing.com
Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock By Investing.com - Investing.com Nigeria
[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity - Stock Titan
Form 4 Phio Pharmaceuticals Corp For: 29 June By Investing.com - Investing.com South Africa
PHIO: PH-762 achieved strong safety and efficacy, with INTASYL poised for broader clinical impact - TradingView
PHIO: PH-762 achieved 85% response with no serious adverse events; next trial planned for early next year - TradingView
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026 - TMX Newsfile
PHIO PHARMACEUTICALS CORP (PHIO) Stock Chart - ChartMill
Phio CEO to pitch INTASYL cancer platform in June 30 webcast - Stock Titan
Phio Pharmaceuticals (PHIO) Life Sciences Virtual Investor Forum Summary - Quartr
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 - EIN News
PHIO Forecast — Price Target — Prediction for 2027 - TradingView
Phio Pharmaceuticals Corp. Actuals & Estimates (MUN:44R1) - TradingView
44R1 Forecast — Price Target — Prediction for 2027 - TradingView
Phio Pharmaceuticals begins commercial-scale production of PH-762 By Investing.com - Investing.com South Africa
Phio Pharmaceuticals begins commercial-scale production of PH-762 - Investing.com
Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026 - The Des Moines Register
PHIO Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesOne-Time Loss Impact - dars.gov.et
PHIO Should I Buy - Intellectia AI
Phio CEO to pitch INTASYL cancer platform at investor forum June 25 - Stock Titan
Phio Pharmaceuticals Corp (PHIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Phio Pharmaceuticals Corp (PHIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Phio Pharmaceuticals Corp (PHIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Phio Pharmaceuticals Corp (PHIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Phio Pharmaceuticals Corp (PHIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Phio Pharmaceuticals Corp (PHIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Phio Pharmaceuticals Corp (PHIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Phio Pharmaceuticals Corp (PHIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Phio Pharmaceuticals Corp (PHIO) Institutional Confidence - TradingKey
PHIO Q1 2026 Earnings: EPS Miss Widens as Clinical-Stage Biotech Continues R&D InvestmentEarnings Sentiment Score - newsline.com
PHIO Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesDividend Earnings Report - newsline.com
PHIO Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Reports ResultsProfit Inflection Point - newsline.com
Number of shareholders of Phio Pharmaceuticals Corp. – MUN:44R1 - TradingView
Phio Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as R&D Spending IntensifiesEPS Growth Report - dars.gov.et
Phio Pharmaceuticals Slides 2.6% as Selling Pressure PersistsStock Analysis - dars.gov.et
Phio Pharmaceuticals Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Biotech Reports No Revenue - The Legal Advocate
Phio Pharmaceuticals (PHIO) Edges Higher, Testing Key Resistance at $1.17Reversal Setup Alerts - newsline.com
PHIOPhio Pharmaceuticals Corp Short Interest - Finviz
Phio Pharmaceuticals Shares Tick Higher as CEO Hits the Road; Traders Eye Small Biotech - Bez Kabli
PHIO Q1 2026 Earnings: EPS Misses Estimates Amid Continued Clinical Trials FocusRevenue Beat Analysis - The Legal Advocate
Skin cancer treatment PH-762: Phio live Q&A session May 28 - Stock Titan
Phio Pharmaceuticals Holds Steady Near Support Levels; PHIO Stock Consolidates in Narrow RangeMA Cross Alert - The Legal Advocate
PHIO Q1 2026 Earnings: Wider-than-Expected Loss Reflects Ongoing R&D InvestmentInvestor Earnings Call - thelegaladvocate.com
Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):